


## CLAIMS

1. An antibiotic, caprazamycin A, caprazamycin B, caprazamycin C, caprazamycin E or caprazamycin F, which is a compound represented by the following general formula


5 (I)



wherein R is tridecyl group for caprazamycin A; 11-methyl-dodecyl group for caprazamycin B; dodecyl group for caprazamycin C; undecyl group for caprazamycin E; and 9-methyl-decyl group for caprazamycin F, or a pharmaceutically acceptable salt thereof.


2. An antibiotic as claimed in Claim 1, which is caprazamycin A represented by the following formula (Ia)

25




that is, the compound of general formula (I) shown in Claim 1 where R is tridecyl group  $-(CH_2)_{12}-CH_3$ .


3. An antibiotic as claimed in Claim 1, which is caprazamycin B represented by the following formula (Ib)



that is, the compound of general formula (I) shown in Claim 1 where R is 11-methyl-dodecyl group




4. An antibiotic as claimed in Claim 1, which is  
5 caprazamycin C represented by the following formula (Ic)



that is, the compound of general formula (I) shown in  
Claim 1 where R is dodecyl group  $\text{---}(\text{CH}_2)_{11}\text{---CH}_3$ .


5. An antibiotic as claimed in Claim 1, which is  
20 caprazamycin E represented by the following formula (Ie)




that is, the compound of general formula (I) shown in Claim 1 where R is undecyl group  $-(CH_2)_{10}-CH_3$ .

6. An antibiotic as claimed in Claim 1, which is caprazamycin F represented by the following formula (If)

15



that is, the compound of general formula (I) shown in Claim 1 where R is 9-methyl-decyl group



7. A process for the production of an antibiotic,  
 5 caprazamycin A, caprazamycin B, caprazamycin C,  
 caprazamycin E and/or caprazamycin F represented by the  
 general formula (I) given in Claim 1, characterized in  
 that the process comprises culturing a microbial strain  
 which belongs to the genus Streptomyces and which is  
 10 capable of producing at least one of caprazamycin A,  
 caprazamycin B, caprazamycin C, caprazamycin E and  
 caprazamycin F, and recovering at least one of  
 caprazamycins A, B, C, E and F from the resulting culture.

8. A process as claimed in Claim 7, wherein as  
 15 the microbial strain capable of producing at least one of  
 caprazamycins A, B, C, E and F, there is used Streptomyces  
 sp. MK730-62F2 which has been deposited in the National  
 Institute of Bioscience and Human-Technology, Agency of  
 Industrial Science and Technology, under the deposit  
 20 number of "FERM BP-7218" in terms of the Budapest Treaty.

9. A pharmaceutical composition comprising as an  
 active ingredient at least one of caprazamycins A, B, C, E  
 and F having the general formula (I) given in Claim 1, or  
 a salt thereof, in admixture with a pharmaceutically  
 25 acceptable carrier or carriers.

10. A composition as claimed in Claim 9, which is  
 an antibacterial composition.

11. As a novel microorganism, Streptomyces sp.

206050-0266400T

5

100-443887-100

15

20

25